Trials / Active Not Recruiting
Active Not RecruitingNCT06253221
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (Age 12 Years to < 18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mavacamten | Specified dose on specified days |
| DRUG | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2024-04-17
- Primary completion
- 2025-11-25
- Completion
- 2031-03-28
- First posted
- 2024-02-12
- Last updated
- 2025-12-19
Locations
47 sites across 9 countries: United States, Australia, Canada, France, Germany, Ireland, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06253221. Inclusion in this directory is not an endorsement.